Stay updated with breaking news from Additional Dose Exploration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to... | April 12, 2023
Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May... | April 12, 2023